{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:50:33Z","timestamp":1771066233321,"version":"3.50.1"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular and Cellular Neuroscience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mcn.2025.104037","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:20:16Z","timestamp":1757514016000},"page":"104037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Covalent inhibitors in Parkinson's disease: Molecular targeting strategies for neuroprotective intervention"],"prefix":"10.1016","volume":"135","author":[{"given":"Devadharuna","family":"Mohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghul","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarjith Thiyyar","family":"Kandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhoshkumar","family":"Muthu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saravanan","family":"Jayaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajinikanth","family":"Baskaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Palanisamy","family":"Pethappachetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divakar","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcn.2025.104037_bb0005","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejmech.2018.10.010","article-title":"A road map for prioritizing warheads for cysteine targeting covalent inhibitors","volume":"160","author":"\u00c1br\u00e1nyi-Balogh","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0010","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/emboj\/18.5.1321","article-title":"Regulation of JNK signaling by GSTp","volume":"18","author":"Adler","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.mcn.2025.104037_bb0015","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1570159X16666180830100754","article-title":"Different generations of type-B monoamine oxidase inhibitors in Parkinson\u2019s disease: from bench to bedside","volume":"17","author":"Alborghetti","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.mcn.2025.104037_bb0020","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1111\/j.1742-4658.2009.07341.x","article-title":"LRRK2 in Parkinson\u2019s disease: biochemical functions","volume":"276","author":"Anand","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.mcn.2025.104037_bb0025","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1021\/acschembio.0c00104","article-title":"Obtusaquinone: a cysteine-modifying compound that targets Keap1 for degradation","volume":"15","author":"Badr","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/17460441.2021.1832079","article-title":"Approaches to mitigate the risk of serious adverse reactions in covalent drug design","volume":"16","author":"Baillie","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.mcn.2025.104037_bb0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.drudis.2015.05.005","article-title":"Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies","volume":"20","author":"Bauer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.mcn.2025.104037_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-015-0066-z","article-title":"LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate","volume":"11","author":"Belluzzi","year":"2016","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.mcn.2025.104037_bb0045","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1021\/bi100157u","article-title":"Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation","volume":"49","author":"Berger","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.mcn.2025.104037_bb0050","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3390\/ph16091295","article-title":"An innovative approach to address neurodegenerative diseases through kinase-targeted therapies: potential for designing covalent inhibitors","volume":"16","author":"Bhujbal","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.mcn.2025.104037_bb0055","doi-asserted-by":"crossref","first-page":"9750","DOI":"10.1073\/pnas.1633804100","article-title":"Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures","volume":"100","author":"Binda","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mcn.2025.104037_bb0060","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1021\/jm031087c","article-title":"Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class","volume":"47","author":"Binda","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0070","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mds.27556","article-title":"Gut\u2013brain axis and the spread of \u03b1-synuclein pathology: vagal highway or dead end?","volume":"34","author":"Breen","year":"2019","journal-title":"Mov. Disord."},{"key":"10.1016\/j.mcn.2025.104037_bb0075","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/molecules27082561","article-title":"Covalent reversible inhibitors of cysteine proteases containing the nitrile warhead: recent advancement in the field of viral and parasitic diseases","volume":"27","author":"Brogi","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.mcn.2025.104037_bb0080","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.3390\/ijms23073705","article-title":"Atypical ubiquitination and Parkinson\u2019s disease","volume":"23","author":"Buneeva","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcn.2025.104037_bb0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/mds.25096","article-title":"New synaptic and molecular targets for neuroprotection in Parkinson\u2019s disease","volume":"28","author":"Calabresi","year":"2013","journal-title":"Mov. Disord."},{"issue":"10","key":"10.1016\/j.mcn.2025.104037_bb0090","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/1873-3468.12177","article-title":"S-Glutathionylation of Keap1: a new role for glutathione S-transferase pi in neuronal protection","volume":"590","author":"Carvalho","year":"2016","journal-title":"FEBS Lett."},{"issue":"16","key":"10.1016\/j.mcn.2025.104037_bb0095","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1002\/anie.201707875","article-title":"The cysteinome of protein kinases as a target in drug development","volume":"57","author":"Chaikuad","year":"2018","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.mcn.2025.104037_bb0100","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1111\/jnc.16092","article-title":"Pharmacologic activation of activating transcription factor 6 contributes to neuronal survival after spinal cord injury in mice","volume":"168","author":"Chang","year":"2024","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2025.104037_bb0105","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.biocel.2012.04.021","article-title":"Crosstalk between Nrf2 and the proteasome: therapeutic potential of Nrf2 inducers in vascular disease and aging","volume":"44","author":"Chapple","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1021\/acs.biochem.8b01161","article-title":"Efficient detection of early events of \u03b1-synuclein aggregation using a cysteine specific hybrid scaffold","volume":"58","author":"Chatterjee","year":"2019","journal-title":"Biochemistry"},{"key":"10.1016\/j.mcn.2025.104037_bb0115","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the \u03b1-synuclein protofibril by a dopamine-\u03b1-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.mcn.2025.104037_bb0120","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/jacs.7b08979","article-title":"Selectively targeting the kinome-conserved lysine of PI3K\u03b4 as a general approach to covalent kinase inhibition","volume":"140","author":"Dalton","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mcn.2025.104037_bb0125","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4155\/fmc-2020-0236","article-title":"10 years into the resurgence of covalent drugs","volume":"13","author":"De Vita","year":"2021","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0130","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S1474-4422(15)00006-X","article-title":"Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations","volume":"14","author":"Dehay","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.mcn.2025.104037_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120196","article-title":"The pathophysiology of Parkinson\u2019s disease tremor","volume":"435","author":"Dirkx","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.mcn.2025.104037_bb0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.nbd.2016.05.011","article-title":"Ferroptosis, a newly characterized form of cell death in Parkinson\u2019s disease that is regulated by PKC","volume":"94","author":"Do Van","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.mcn.2025.104037_bb0145","doi-asserted-by":"crossref","first-page":"8645","DOI":"10.3390\/ijms21228645","article-title":"The role of \u03b1-synuclein oligomers in Parkinson\u2019s disease","volume":"21","author":"Du","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mcn.2025.104037_bb0150","series-title":"Monoamine Oxidases","first-page":"117","volume":"87","author":"Edmondson","year":"2018"},{"key":"10.1016\/j.mcn.2025.104037_bb0155","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.2174\/0929867043364784","article-title":"Structure and mechanism of monoamine oxidase","volume":"11","author":"Edmondson","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0160","doi-asserted-by":"crossref","first-page":"22243","DOI":"10.1074\/jbc.M301211200","article-title":"Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase pi*","volume":"278","author":"Elsby","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0165","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1021\/cb300663j","article-title":"Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features","volume":"8","author":"Fang","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0170","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.115.227587","article-title":"MLi-2, a potent, selective, and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition","volume":"355","author":"Fell","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.mcn.2025.104037_bb0175","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1021\/acschemneuro.7b00017","article-title":"An ortho-iminoquinone compound reacts with lysine inhibiting aggregation while remodeling mature amyloid fibrils","volume":"8","author":"Fernandes","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.mcn.2025.104037_bb0180","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10003","article-title":"Pharmacology of rasagiline, a new MAO-B inhibitor drug for the treatment of Parkinson\u2019s disease with neuroprotective potential","volume":"1","author":"Finberg","year":"2010","journal-title":"Rambam Maimonides Med. J."},{"key":"10.1016\/j.mcn.2025.104037_bb0185","doi-asserted-by":"crossref","first-page":"11734","DOI":"10.1021\/jacs.9b13907","article-title":"Efficient targeted degradation via reversible and irreversible covalent PROTACs","volume":"142","author":"Gabizon","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.mcn.2025.104037_bb0250","doi-asserted-by":"crossref","first-page":"5673","DOI":"10.1021\/acs.jmedchem.8b01153","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: applications in medicinal chemistry and chemical biology","volume":"62","author":"Gehringer","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0190","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/cmdc.201900107","article-title":"Covalent inhibition in drug discovery","volume":"14","author":"Ghosh","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.mcn.2025.104037_bb0195","doi-asserted-by":"crossref","first-page":"5473","DOI":"10.1021\/acs.jmedchem.3c02097","article-title":"Combinatorial ubiquitination REal-time PROteolysis (CURE-PROs): a modular platform for generating reversible, self-assembling bifunctional targeted degraders","volume":"67","author":"Giardina","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0200","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1039\/D1MD00191D","article-title":"Covalent PROTACs: the best of both worlds?","volume":"12","author":"Grimster","year":"2021","journal-title":"RSC Med Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0205","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1074\/jbc.M116.750299","article-title":"Structural and biochemical analyses reveal the mechanism of glutathione S-transferase pi 1 inhibition by the anti-cancer compound piperlongumine*","volume":"292","author":"Harshbarger","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0210","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1021\/acsmedchemlett.5b00064","article-title":"Discovery of a pyrrolopyrimidine (JH-II-127), a highly potent, selective, and brain penetrant LRRK2 inhibitor","volume":"6","author":"Hatcher","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.mcn.2025.104037_bb0215","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.jmb.2013.01.038","article-title":"Hidden allostery in human glutathione transferase P1-1 unveiled by unnatural amino acid substitutions and inhibition studies","volume":"425","author":"Hegazy","year":"2013","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0220","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.febslet.2011.01.009","article-title":"The role of the C-terminus of human \u03b1-synuclein: intra-disulfide bonds between the C-terminus and other regions stabilize non-fibrillar monomeric isomers","volume":"585","author":"Hong","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.mcn.2025.104037_bb0225","series-title":"Mitochondrial DNA Dis [Internet]","first-page":"133","article-title":"Beyond deubiquitylation: USP30-mediated regulation of mitochondrial homeostasis","author":"Hou","year":"2017"},{"key":"10.1016\/j.mcn.2025.104037_bb0230","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40035-016-0060-6","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"5","author":"Hu","year":"2016","journal-title":"Transl Neurodegener."},{"key":"10.1016\/j.mcn.2025.104037_bb0235","doi-asserted-by":"crossref","DOI":"10.1063\/5.0188714","article-title":"In situ single-molecule investigations of the impacts of biochemical perturbations on conformational intermediates of monomeric \u03b1-synuclein","volume":"8","author":"Huang","year":"2024","journal-title":"APL Bioeng."},{"key":"10.1016\/j.mcn.2025.104037_bb0240","doi-asserted-by":"crossref","DOI":"10.3390\/life11070607","article-title":"Chemical-mediated targeted protein degradation in neurodegenerative diseases","volume":"11","author":"Hyun","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.mcn.2025.104037_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/biof.2086","article-title":"Catechol-induced covalent modifications modulate the aggregation tendency of \u03b1-synuclein: an in-solution and in-silico study","volume":"51","author":"Inciardi","year":"2025","journal-title":"Biofactors"},{"key":"10.1016\/j.mcn.2025.104037_bb0255","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1021\/acs.jmedchem.3c02410","article-title":"Development of inhibitors, probes, and PROTAC provides a complete toolbox to study PARK7 in the living cell","volume":"67","author":"Jia","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0260","series-title":"Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis","first-page":"3","author":"John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, UK","year":"2018"},{"key":"10.1016\/j.mcn.2025.104037_bb0265","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4155\/fmc.10.21","article-title":"Strategies for discovering and derisking covalent, irreversible enzyme inhibitors","volume":"2","author":"Johnson","year":"2010","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0270","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/j.bmcl.2018.05.013","article-title":"Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy","volume":"28","author":"Kluge","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.mcn.2025.104037_bb0275","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1039\/D0CC00523A","article-title":"A caged E3 ligase ligand for PROTAC-mediated protein degradation with light","volume":"56","author":"Kounde","year":"2020","journal-title":"Chem. Commun."},{"key":"10.1016\/j.mcn.2025.104037_bb0280","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1002\/anie.201201955","article-title":"Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors","volume":"51","author":"Krysiak","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.mcn.2025.104037_bb0285","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1471-4159.2007.04743.x","article-title":"Leucine-rich repeat kinase 2 (LRRK2)\/PARK8 possesses GTPase activity that is altered in familial Parkinson\u2019s disease R1441C\/G mutants","volume":"103","author":"Li","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.mcn.2025.104037_bb0290","doi-asserted-by":"crossref","first-page":"10821","DOI":"10.1002\/anie.201504441","article-title":"A small-molecule probe for selective profiling and imaging of monoamine oxidase B activities in models of Parkinson\u2019s disease","volume":"54","author":"Li","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.mcn.2025.104037_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2021.112967","article-title":"MF-094, a potent and selective USP30 inhibitor, accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome","volume":"410","author":"Li","year":"2022","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.mcn.2025.104037_bb0300","doi-asserted-by":"crossref","first-page":"32937","DOI":"10.1074\/jbc.M114.602318","article-title":"Unique functional and structural properties of the LRRK2 protein ATP-binding pocket","volume":"289","author":"Liu","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0305","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1042\/bse0560137","article-title":"Oligomers of \u03b1-synuclein: picking the culprit in the line-up. Perrett S, editor","volume":"56","author":"Lorenzen","year":"2014","journal-title":"Essays Biochem."},{"key":"10.1016\/j.mcn.2025.104037_bb0310","doi-asserted-by":"crossref","first-page":"5468","DOI":"10.1021\/ja300094r","article-title":"Semisynthetic, site-specific ubiquitin modification of \u03b1-synuclein reveals differential effects on aggregation","volume":"134","author":"Meier","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mcn.2025.104037_bb0315","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.chembiol.2021.06.005","article-title":"Bifunctional modalities for repurposing protein function","volume":"28","author":"Modell","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109676","article-title":"The art of suicidal molecular seduction for targeting drug resistance","volume":"140","author":"Moshafi","year":"2020","journal-title":"Med. Hypotheses"},{"issue":"8","key":"10.1016\/j.mcn.2025.104037_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2023.100609","article-title":"Structural premise of selective deubiquitinase USP30 inhibition by small-molecule benzosulfonamides","volume":"22","author":"O'Brien","year":"2023","journal-title":"Mol. Cell. Proteomics"},{"issue":"2","key":"10.1016\/j.mcn.2025.104037_bb0330","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1021\/acs.jproteome.4c00618","article-title":"Structural dynamics of the ubiquitin specific protease USP30 in complex with a cyanopyrrolidine-containing covalent inhibitor","volume":"24","author":"O'Brien","year":"2025","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.mcn.2025.104037_bb0335","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.redox.2017.01.006","article-title":"Modulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseases","volume":"11","author":"Pajares","year":"2017","journal-title":"Redox Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40120-024-00680-z","article-title":"Long-term safety and effectiveness of dimethyl fumarate in patients with multiple sclerosis treated in routine medical practice: final analysis of the ESTEEM study","volume":"14","author":"Pandey","year":"2025","journal-title":"Neurol Ther."},{"key":"10.1016\/j.mcn.2025.104037_bb0345","doi-asserted-by":"crossref","first-page":"8876","DOI":"10.1021\/bi00100a022","article-title":"Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate","volume":"30","author":"Patston","year":"1991","journal-title":"Biochemistry"},{"key":"10.1016\/j.mcn.2025.104037_bb0350","article-title":"G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage","volume":"10","author":"Pena","year":"2024","journal-title":"Npj Park Dis."},{"key":"10.1016\/j.mcn.2025.104037_bb0355","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.arr.2015.12.002","article-title":"Lysines, Achilles\u2019 heel in alpha-synuclein conversion to a deadly neuronal endotoxin","volume":"26","author":"Plotegher","year":"2016","journal-title":"Ageing Res. Rev."},{"issue":"14","key":"10.1016\/j.mcn.2025.104037_bb0065","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acs.biochem.7b00151","article-title":"Covalent allosteric inactivation of protein tyrosine phosphatase 1B (PTP1B) by an inhibitor-electrophile conjugate","volume":"56","author":"Punthasee","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.mcn.2025.104037_bb0360","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1021\/bi8002378","article-title":"Characterization of \u03b1-synuclein interactions with selected aggregation-inhibiting small molecules","volume":"47","author":"Rao","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.mcn.2025.104037_bb0365","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1021\/acschembio.1c00810","article-title":"Metabolically activated proteostasis regulators protect against glutamate toxicity by activating NRF2","volume":"16","author":"Rosarda","year":"2021","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105422","article-title":"Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)","volume":"165","author":"Roskoski","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mcn.2025.104037_bb0375","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060006","article-title":"Conformational equilibria in monomeric \u03b1-synuclein at the single-molecule level","volume":"6","author":"Sandal","year":"2008","journal-title":"PLoS Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0380","doi-asserted-by":"crossref","first-page":"12702","DOI":"10.1021\/jacs.4c02262","article-title":"A targetable N-terminal motif orchestrates \u03b1-synuclein oligomer-to-fibril conversion","volume":"146","author":"Santos","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.mcn.2025.104037_bb0385","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s42269-023-01047-4","article-title":"A detailed review of pathophysiology, epidemiology, cellular and molecular pathways involved in the development and prognosis of Parkinson\u2019s disease with insights into screening models","volume":"47","author":"Sayyaed","year":"2023","journal-title":"Bull. Natl. Res. Cent."},{"key":"10.1016\/j.mcn.2025.104037_bb0390","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1021\/acs.jmedchem.7b00045","article-title":"Discovery of a 3-(4-pyrimidinyl) indazole (MLi-2), an orally available and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor that reduces brain kinase activity","volume":"60","author":"Scott","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0395","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2353\/ajpath.2009.081019","article-title":"Identification of glutathione S-transferase pi as a protein involved in Parkinson disease progression","volume":"175","author":"Shi","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.mcn.2025.104037_bb0400","doi-asserted-by":"crossref","first-page":"11138","DOI":"10.1039\/C7CC05829B","article-title":"A covalent G-site inhibitor for glutathione S-transferase Pi (GSTP1-1)","volume":"53","author":"Shishido","year":"2017","journal-title":"Chem. Commun."},{"key":"10.1016\/j.mcn.2025.104037_bb0405","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2018.06.013","article-title":"Canonical and non-canonical mechanisms of Nrf2 activation","volume":"134","author":"Silva-Islas","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mcn.2025.104037_bb0410","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cbpa.2010.06.168","article-title":"Targeted covalent drugs of the kinase family","volume":"14","author":"Singh","year":"2010","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0415","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd3410","article-title":"The resurgence of covalent drugs","volume":"10","author":"Singh","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.mcn.2025.104037_bb0420","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1021\/acschembio.3c00330","article-title":"Covalent targeting as a common mechanism for inhibiting NLRP3 inflammasome assembly","volume":"19","author":"Stanton","year":"2024","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.mcn.2025.104037_bb0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jnutbio.2017.09.016","article-title":"Sulforaphane attenuates postnatal proteasome inhibition and improves spatial learning in adult mice","volume":"51","author":"Sunkaria","year":"2018","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.mcn.2025.104037_bb0430","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/D0MD00154F","article-title":"Covalent inhibitors: a rational approach to drug discovery","volume":"11","author":"Sutanto","year":"2020","journal-title":"RSC Med Chem."},{"key":"10.1016\/j.mcn.2025.104037_bb0435","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00702-019-02082-0","article-title":"Selegiline: a molecule with innovative potential","volume":"127","author":"T\u00e1bi","year":"2020","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.mcn.2025.104037_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/antib12030043","article-title":"Proteolysis-targeting chimera (PROTAC) delivery into the brain across the blood-brain barrier","volume":"12","author":"Tashima","year":"2023","journal-title":"Antibodies"},{"key":"10.1016\/j.mcn.2025.104037_bb0450","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1042\/BST20120133","article-title":"The GTPase function of LRRK2","volume":"40","author":"Taymans","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.mcn.2025.104037_bb0455","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/genes13081426","article-title":"Structural insights and development of LRRK2 inhibitors for Parkinson\u2019s disease in the last decade","volume":"13","author":"Thakur","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.mcn.2025.104037_bb0460","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1093\/brain\/awx172","article-title":"Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders","volume":"140","author":"Tong","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.mcn.2025.104037_bb0465","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/13543784.2016.1237501","article-title":"Investigational \u03b1-synuclein aggregation inhibitors: hope for Parkinson\u2019s disease","volume":"25","author":"T\u00f6r\u00f6k","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.mcn.2025.104037_bb0470","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1021\/ja211042r","article-title":"Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-\u03b2- d -ribofuranose 2\u2032-oxidase DprE1","volume":"134","author":"Trefzer","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.mcn.2025.104037_bb0475","first-page":"1356","article-title":"Mitochondrial complex I as a pathologic and therapeutic target for Parkinson\u2019s disease","volume":"14","author":"Tryphena","year":"2023","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.mcn.2025.104037_bb0480","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1111\/febs.13305","article-title":"Cellular processes associated with LRRK2 function and dysfunction","volume":"282","author":"Wallings","year":"2015","journal-title":"FEBS J."},{"key":"10.1016\/j.mcn.2025.104037_bb0485","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/0040-4020(82)85068-0","article-title":"Suicide substrates: mechanism-based enzyme inactivators","volume":"38","author":"Walsh","year":"1982","journal-title":"Tetrahedron"},{"key":"10.1016\/j.mcn.2025.104037_bb0490","article-title":"USP30: structure, emerging physiological role, and target inhibition","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mcn.2025.104037_bb0495","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.expneurol.2017.07.019","article-title":"Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease","volume":"298","author":"West","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.mcn.2025.104037_bb0500","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1038\/sj.onc.1209576","article-title":"Human glutathione S-transferase P1-1 interacts with TRAF2 and regulates TRAF2\u2013ASK1 signals","volume":"25","author":"Wu","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.mcn.2025.104037_bb0505","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1042\/BST20120093","article-title":"LRRK2 GTPase dysfunction in the pathogenesis of Parkinson\u2019s disease","volume":"40","author":"Xiong","year":"2012","journal-title":"Biochem. Soc. Trans."},{"issue":"19","key":"10.1016\/j.mcn.2025.104037_bb0510","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1016\/j.febslet.2005.06.034","article-title":"Regulation of lipopolysaccharide-induced inflammatory response by glutathione S-transferase P1 in RAW264.7 cells","volume":"579","author":"Xue","year":"2005","journal-title":"FEBS Lett."},{"key":"10.1016\/j.mcn.2025.104037_bb0515","article-title":"Role of Nrf2 in Parkinson\u2019s disease: toward new perspectives","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mcn.2025.104037_bb0520","series-title":"Parkinson Disease. StatPearls [Internet]","author":"Zafar","year":"2025"},{"key":"10.1016\/j.mcn.2025.104037_bb0525","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40035-023-00378-6","article-title":"Role of dopamine in the pathophysiology of Parkinson\u2019s disease","volume":"12","author":"Zhou","year":"2023","journal-title":"Transl Neurodegener."},{"issue":"23","key":"10.1016\/j.mcn.2025.104037_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313042","article-title":"Targeting ferroptosis in Parkinson's disease: mechanisms and emerging therapeutic strategies","volume":"25","author":"Zhou","year":"2024","journal-title":"Int. J. Mol. Sci."}],"container-title":["Molecular and Cellular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743125000478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044743125000478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T17:37:30Z","timestamp":1764956250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044743125000478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":105,"alternative-id":["S1044743125000478"],"URL":"https:\/\/doi.org\/10.1016\/j.mcn.2025.104037","relation":{},"ISSN":["1044-7431"],"issn-type":[{"value":"1044-7431","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Covalent inhibitors in Parkinson's disease: Molecular targeting strategies for neuroprotective intervention","name":"articletitle","label":"Article Title"},{"value":"Molecular and Cellular Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcn.2025.104037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104037"}}